Last edition
News about "immune-disorder drug in deal "
Biogen licences Vanqua Bio's immune-disorder drug in deal worth up to USD 1.06 billion
Biogen has entered into an agreement with Vanqua Bio to acquire global rights to an experimental oral therapy for immune-related disorders, in a deal valued at up to USD 1.06 billion.
Immune-disorder Drug In Deal | 27/10/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members